Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Jenner Institute, MilliporeSigma to Scale Up Covid-19 Vax Production | Contract Pharma

What are you searching for?

Sign in
Breaking News

Jenner Institute, MilliporeSigma to Scale Up Covid-19 Vax Production

Develops a rapid, scalable platform following good manufacturing practices and using disposable technologies.

By: Contract Pharma

Contract Pharma Staff

The Jenner Institute, along with MilliporeSigma, is preparing for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19. Patients are currently enrolled in clinical trials for the vaccine, which will require rapid development of the large-scale manufacturing process quickly and safely.

Leveraging MilliporeSigma’s previous work allowed for plans to scale-up the manufacture of Jenner’s Covid-19 vaccine candidate. Developing the manufacturing process itself would normally take six months to a year, but in two months, MilliporeSigma supported the Jenner team and their collaborators to evaluate the existing manufacturing platform for use with the new vaccine candidate, and improved critical process steps.

Over the last two years, MilliporeSigma’s collaboration with The Jenner Institute has led to the development of a rapid, scalable platform following good manufacturing practices and using disposable technologies for the institute’s adenovirus platform. Although the initial work was developed with a rabies vaccine candidate, the platform was then validated with different adenovirus constructs aimed at accelerating future vaccine development and manufacturing. The companies first partnered to develop more robust and scalable vaccine manufacturing processes in April 2018.

“We have brought the future of vaccine manufacturing to the present,” said Udit Batra, CEO, MilliporeSigma. “This is an important step in treating Covid-19 and other diseases that impact global public health. This work marks a milestone in the vaccine manufacturing development journey, as clinical testing continues to advance.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics